Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer.

[1]  E Harrison,et al.  Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  L. Saltz,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.

[3]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. Peters,et al.  Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  K. Sugimachi,et al.  Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma , 2000, British Journal of Cancer.

[6]  R. Schilsky,et al.  A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  R. James,et al.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.

[8]  H. Burger,et al.  Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  W. Stolz,et al.  Dermoscopic diagnosis of small melanocytic skin lesions: An inter-observer agreement study by classical pattern and ABCD-rule analyses , 2000 .

[10]  N. Schmitz,et al.  Stem-cell transplantation for chronic lymphocytic leukemia: the 1999 perspective. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  F. Lévi,et al.  Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  B. Reigner,et al.  Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients , 2000, Cancer Chemotherapy and Pharmacology.

[13]  O. Bouché,et al.  Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  H. Ishitsuka,et al.  X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  H. Ishitsuka,et al.  Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′‐deoxy‐5‐fluorouridine by cyclophosphamide in mammary tumor models , 1999, International journal of cancer.

[16]  J. Lotz,et al.  Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. , 1999, European journal of cancer.

[17]  D. Kerr,et al.  Preliminary results of a multicentre randomised trial comparing 3 chemotherapy regimens (De Gramont, Lokich and Raltitrexed) in metastatic colorectal cancer. , 1999 .

[18]  Christian Jacques,et al.  Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer , 1998, The Lancet.

[19]  R. Labianca,et al.  Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer , 1998, The Lancet.

[20]  N. Meropol.  Oral fluoropyrimidines in the treatment of colorectal cancer. , 1998, European journal of cancer.

[21]  D. Kerr,et al.  Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  H. Ishitsuka,et al.  Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. , 1998, European journal of cancer.

[23]  B. Reigner,et al.  Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  H. Ishitsuka,et al.  Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. , 1998, Biochemical pharmacology.

[25]  H. Ishitsuka,et al.  Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  H. Ishitsuka,et al.  Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. , 1998, Cancer research.

[27]  Y. Rustum,et al.  Rationale for treatment design: biochemical modulation of 5-fluorouracil by leucovorin. , 1998, The cancer journal from Scientific American.

[28]  M. Buyse,et al.  Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Grem.  Systemic treatment options in advanced colorectal cancer: perspectives on combination 5-fluorouracil plus leucovorin. , 1997, Seminars in oncology.

[30]  P. Rougier,et al.  Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  C. Tournigand,et al.  Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. , 1997, European journal of cancer.

[32]  E. Warner,et al.  Patient preferences for oral versus intravenous palliative chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  D. Kerr,et al.  Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  H. Schmoll.  Development of treatment for advanced colorectal cancer: infusional 5-FU and the role of new agents. , 1996, European journal of cancer.

[35]  M. Ychou,et al.  Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  F. Cappuzzo,et al.  Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  J. P. Pignon,et al.  Efficacy of adjuvant fluorouracil and folinic acid in colon cancer International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators , 1995, The Lancet.

[38]  J. Ajani,et al.  Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  N. Kemeny.  Current approaches to metastatic colorectal cancer. , 1994, Seminars in oncology.

[40]  S. Payne.  A study of quality of life in cancer patients receiving palliative chemotherapy. , 1992, Social science & medicine.

[41]  P. Piedbois.  Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  H. Wieand,et al.  Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  S. Barni,et al.  Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of 'GISCAD' (Italian Group for the Study of Digestive Tract Cancer). , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  Michael R. Green,et al.  The Modulation of Fluorouracil With Leucovorin in Metastatic Colorectal Carcinoma A Prospective Randomized Phase III Trial , 1990 .

[45]  J. Laurie,et al.  Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  N. Petrelli,et al.  The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Robert B. Diasio,et al.  Clinical Pharmacology of 5-Fluorouracil , 1989, Clinical pharmacokinetics.

[48]  T. Tashiro,et al.  Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data. , 1989, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.